Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
97
Active, not recruiting, industry sponsors, Immunology and inflammation, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,102
97 trials
Showing 1 to 25, recently updated first.
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05197049 · 350 participants · Start Jan 19, 2022 · Primary completion Jul 4, 2023
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 2 more · For: Crohn Disease
Sites: Dothan, Alabama; Chandler, Arizona; Scottsdale, Arizona · 345 sites in all
- Vagus Nerve Stimulation for Moderate to Severe Rheumatoid ArthritisPivotal-lookingActive, not recruiting
SetPoint Medical CorporationIndustry
NCT04539964 · 243 participants · Start Jan 11, 2021 · Primary completion May 16, 2024
Drug: Conventional Synthetic DMARD · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 43 sites in all
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPivotal-lookingActive, not recruiting
MoonLake Immunotherapeutics AGIndustry
NCT06641076 · 960 participants (planned) · Start Oct 15, 2024 · Primary completion May 28, 2026
Drug: Sonelokimab; Placebo · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 182 sites in all
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePivotal-lookingActive, not recruiting
MoonLake Immunotherapeutics AGIndustry
NCT06641089 · 600 participants (planned) · Start Oct 15, 2024 · Primary completion Jan 4, 2027
Drug: Sonelokimab; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 143 sites in all
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06671483 · 1,583 participants · Start Mar 3, 2025 · Primary completion May 18, 2027
Drug: Zasocitinib; Active Comparator and 1 more · For: Psoriatic Arthritis
Sites: Chandler, Arizona; Phoenix, Arizona; Fountain Valley, California · 184 sites in all
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04963296 · 303 participants · Start Oct 26, 2021 · Primary completion Sep 15, 2025
Drug: Obinutuzumab; Placebo and 3 more · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Searcy, Arkansas; Fullerton, California · 63 sites in all
- A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06807268 · 151 participants · Start Jul 24, 2025 · Primary completion May 2, 2027
Drug: Abrocitinib · For: Eczema
Sites: Birmingham, Alabama; North Little Rock, Arkansas; San Diego, California · 47 sites in all
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisPivotal-lookingActive, not recruiting
Organon and CoIndustry
NCT07265479 · 187 participants · Start Dec 29, 2025 · Primary completion Aug 2027
Drug: Tapinarof cream, 1%; Vehicle Cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Bryant, Arkansas; Los Angeles, California · 46 sites in all
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT03950232 · 896 participants · Start Sep 5, 2019 · Primary completion Jun 19, 2029
Drug: Etrasimod · For: Ulcerative Colitis
Sites: Dothan, Alabama; Lake Elsinore, California; Lancaster, California · 472 sites in all
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095115 · 684 participants · Start Oct 12, 2023 · Primary completion Jul 29, 2024
Drug: JNJ-77242113; Placebo · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Fort Smith, Arkansas; Fountain Valley, California · 170 sites in all
- A Study of Guselkumab in Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04882098 · 1,054 participants · Start Jun 17, 2021 · Primary completion Dec 30, 2024
Drug: Guselkumab; Placebo · For: Arthritis, Psoriatic
Sites: Birmingham, Alabama; Flagstaff, Arizona; Glendale, Arizona · 280 sites in all
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04033445 · 1,064 participants · Start Sep 26, 2019 · Primary completion Sep 19, 2023
Drug: Placebo; Guselkumab · For: Ulcerative Colitis
Sites: Lancaster, California; Los Angeles, California; Colorado Springs, Colorado · 392 sites in all
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06220604 · 731 participants · Start Mar 9, 2024 · Primary completion Nov 15, 2024
Drug: JNJ-77242113; JNJ-77242113 Matching Placebo and 2 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Encinitas, California; Encino, California · 128 sites in all
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05528510 · 418 participants · Start Sep 13, 2022 · Primary completion Apr 2, 2024
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 1 more · For: Colitis, Ulcerative
Sites: Litchfield Park, Arizona; Apple Valley, California; Lancaster, California · 236 sites in all
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06143878 · 774 participants · Start Jan 17, 2024 · Primary completion Sep 17, 2024
Drug: JNJ-77242113; JNJ-77242113 Matching Placebo and 2 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fort Smith, Arkansas · 164 sites in all
- A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095102 · 311 participants · Start Oct 12, 2023 · Primary completion Jun 19, 2024
Drug: JNJ-77242113; Placebo · For: Plaque Psoriasis
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Encinitas, California · 90 sites in all
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06878404 · 552 participants · Start Feb 21, 2025 · Primary completion May 25, 2026
Drug: Icotrokinra; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Jonesboro, Arkansas; DeBary, Florida; Plantation, Florida · 155 sites in all
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03466411 · 1,409 participants · Start Apr 13, 2018 · Primary completion Oct 20, 2023
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 6 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Tucson, Arizona · 579 sites in all
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
NCT05347095 · 288 participants · Start Sep 27, 2022 · Primary completion Mar 25, 2027
Drug: Guselkumab; Placebo · For: Fistulizing Crohns Disease; Perianal Crohns Disease
Sites: Birmingham, Alabama; New Haven, Connecticut; Miami, Florida · 154 sites in all
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsPivotal-lookingActive, not recruiting
Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
NCT06408935 · 120 participants · Start Apr 17, 2024 · Primary completion Jun 8, 2027
Drug: Guselkumab · For: Crohn's Disease
Sites: San Francisco, California; Chicago, Illinois; St Louis, Missouri · 84 sites in all
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06260163 · 112 participants · Start Jan 19, 2024 · Primary completion Feb 10, 2027
Drug: Guselkumab Subcutaneous; Guselkumab Intravenous · For: Colitis, Ulcerative
Sites: Oakland, California; Indianapolis, Indiana; Lake Success, New York · 61 sites in all
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03451851 · 120 participants · Start Jul 11, 2018 · Primary completion Jul 19, 2023
Drug: Guselkumab; Placebo for guselkumab and 1 more · For: Psoriasis
Sites: Palo Alto, California; San Diego, California; Macon, Georgia · 39 sites in all
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06934226 · 752 participants · Start Apr 15, 2025 · Primary completion Nov 17, 2025
Drug: JNJ-77242113; Matching Placebo to JNJ-77242113 and 2 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Encinitas, California; Encino, California · 160 sites in all
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06807424 · 813 participants · Start Jan 9, 2025 · Primary completion Feb 10, 2027
Drug: Icotrokinra; Placebo · For: Arthritis, Psoriatic
Sites: Glendale, Arizona; Mesa, Arizona; Jonesboro, Arkansas · 236 sites in all
- A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05092269 · 159 participants · Start Oct 18, 2021 · Primary completion Sep 29, 2027
Drug: Ustekinumab · For: Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Sites: Atlanta, Georgia; New York, New York; Charlotte, North Carolina · 48 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.